Info

Arriva Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of anti-inflammatory therapies for the treatment of respiratory diseases. Arriva's current clinical focus is the development of recombinant alpha 1-antitrypsin (rAAT) for hereditary emphysema.